Kenneth Lindegaard Madsen established his scientific core studying protein-protein interactions, focusing on PDZ interactions and the function of the synaptic PDZ domain protein PICK1. In parallel, it became clear that PICK1 might be an attractive molecular target in drug addiction and pain. Using his expertise on PICK1 and PDZ interactions, he developed and patented the first small molecule inhibitors for this type of protein, together with Neurosearch A/S. As an independent researcher, he subsequently solved the PICK1 structure and developed a novel quantitative method for assessing the binding of scaffold proteins to membrane proteins in their native membrane environment. Together, these efforts enabled the rational design and patenting of bivalent, high-affinity inhibitors to potently target PICK1 in pain and addiction. The inhibition of PICK1 is unique in the sense that it selectively targets the hyperexcitable transmission characterizing these pathologies without affecting the overall transmission (Christensen...Madsen, EMBO Mol. Med., 2020, IF 10.6). The understanding of the central and novel peripheral role of PICK1 in chronic pain conditions is currently a major academic undertaking in the lab, whereas the drug development of bivalent PICK1 peptide inhibitors is conducted in the spin-out biotech company DolorestBio.
Kenneth Lindegaard Madsen established his scientific core studying protein-protein interactions, focusing on PDZ interactions and the function of the synaptic PDZ domain protein PICK1. In parallel, it became clear that PICK1 might be an attractive molecular target in drug addiction and pain. Using his expertise on PICK1 and PDZ interactions, he developed and patented the first small molecule inhibitors for this type of protein, together with Neurosearch A/S. As an independent researcher, he subsequently solved the PICK1 structure and developed a novel quantitative method for assessing the binding of scaffold proteins to membrane proteins in their native membrane environment. Together, these efforts enabled the rational design and patenting of bivalent, high-affinity inhibitors to potently target PICK1 in pain and addiction. The inhibition of PICK1 is unique in the sense that it selectively targets the hyperexcitable transmission characterizing these pathologies without affecting the overall transmission (Christensen...Madsen, EMBO Mol. Med., 2020, IF 10.6). The understanding of the central and novel peripheral role of PICK1 in chronic pain conditions is currently a major academic undertaking in the lab, whereas the drug development of bivalent PICK1 peptide inhibitors is conducted in the spin-out biotech company DolorestBio.